Related Experiment Video

Updated: Aug 10, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

Ouabain as an amplifier of mineralocorticoid-induced hypertension

H Sekihara1, Y Yazaki, T Kojima

  • 1Third Department of Internal Medicine, University of Tokyo Faculty of Medicine, Japan.

Endocrinology
|December 1, 1992
PubMed

Insights

Ouabain amplifies the blood pressure-raising effects of mineralocorticoids like deoxycorticosterone acetate (DOCA) in rats. This interaction is crucial for understanding hypertension development, even when ouabain alone does not increase blood pressure.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Renal Physiology

Background:

  • Ouabain is identified as an endogenous inhibitor of Na, K-ATPase.
  • Mineralocorticoids, such as deoxycorticosterone acetate (DOCA), are known to influence blood pressure regulation.

Purpose of the Study:

  • To investigate whether ouabain possesses intrinsic hypertensive properties.
  • To determine if ouabain amplifies the hypertensive effects of low-dose mineralocorticoids.

Main Methods:

  • Mononephrectomized rats received weekly injections of DOCA, ouabain, or a combination over six weeks.
  • Blood pressure, cardionephromegaly, and histopathological changes were evaluated.

Main Results:

  • Neither DOCA nor ouabain alone significantly altered blood pressure compared to controls.
  • Combined administration of DOCA and ouabain resulted in significantly elevated blood pressure.
  • The blood pressure elevation was dose-dependent on ouabain, with amplification observed at 0.25 mg/week.

Conclusions:

  • Ouabain potentiates the hypertensive action of mineralocorticoids without causing hypertension independently.
  • This synergistic effect suggests a significant role for ouabain in the pathogenesis of mineralocorticoid-induced hypertension.

More Related Videos

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney10:00

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney

Published on: October 12, 2015

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...